Skip Ribbon Commands
Skip to main content
Menu
Dr Melinda Tan

Dr Tan Si Yun, Melinda

​​MD, MMed(Int Med), MRCP(UK)

Consultant

Singapore General Hospital

Specialty: Haematology

Sub-specialties: Lymphoma, Myeloma, Laboratory Haematology

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL) , Aplastic Anaemia , Chronic lymphocytic leukemia , Chronic Myeloid Leukemia (CML) , Deep Vein Thrombosis , Deep Vein Thrombosis , essential thrombocythemia , Lymphoma , Multiple Myeloma , Myelodysplastic Syndromes , Myelofibrosis , Myeloma , Polycythemia Vera , Thalassaemia .

Clinical Appointments

  • Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Consultant Haematology Singapore General HospitalSingapore General Hospital
  • Consultant National Cancer Centre SingaporeNational Cancer Centre Singapore

Profile

​Dr Tan received her medical training at the Duke-NUS Medical School. She subsequently joined the department of Haematology as it provides her with the opportunity to treat a wide range of blood disorders, and marries the best of clinical and laboratory medicine. She has a special interest in multiple myeloma and flow cytometry. 

Education

Professional Appointments and Committee Memberships

  • Clinical Tutor – Yong Loo Lin School of Medicine, NUS
  • Clinical Instructor – Duke-NUS Medical School

Awards

  • Singhealth Health Quality Service HERO awards 2021
  • Service Quality Award (Silver) 2019

Research Interests

Publications

  • Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J [Internet]. 2021 Aug 12;11(8):143. Available from:
  • Chen Y, Nagarajan C, Tan MS, Martinelli G, Cerchione C. BCMA-targeting approaches for treatment of multiple myeloma. Panminerva Med [Internet]. 2021 Mar;63(1):28–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32955181
  • Jaya-Bodestyne SL, Lee LH, Tan LK, Tan KH, Østbye T, Malhotra R, et al. Risk factors for pregnancy-associated venous thromboembolism in Singapore. J Perinat Med [Internet]. 2021 Feb 23;49(2):153–8.
  • Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Vol. 11, Blood cancer journal. 2021. p. 150.
  • Nagarajan C, Tan MS, Chen Y, Martinelli G, Cerchione C. Current and future perspectives of maintenance therapy in multiple myeloma. Panminerva Med [Internet]. 2020 Dec;62(4):225–33.
  • Jen W-Y, Yoong J, Liu X, Tan MSY, Chng WJ, Chee Y-L. Qualitative Study of Factors Affecting Patient, Caregiver and Physician Preferences for Treatment of Myeloma and Indolent Lymphoma. Patient Prefer Adherence [Internet]. 2020;14:301–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32109996
  • Chew M-H, Koh P-K, Tan M, Lim K-H, Carol L, Tang C-L. Mismatch repair deficiency screening via immunohistochemical staining in young Asians with colorectal cancers. World J Surg. 2013 Oct;37(10):2468–75.
  • Tan MSY, Narasimhalu K, Ong SYK. Letting the cat out of the bag: shifting practices of cancer disclosure in Singapore. Singapore Med J. 2012 May;53(5):344–8.
      

Research Trials